CD226 and melanoma: NY-ESO-1-specific CD8+TILs express low levels of CD226 and high levels of TIGIT and PD-1 in melanoma patients, but this imbalance is not found in circulating CD8+T cells regardless of specificity for NY-ESO-1 [50].